García-Huerta, Paula
Troncoso-Escudero, Paulina
Wu, Di
Thiruvalluvan, Arun
Cisternas-Olmedo, Marisol
Henríquez, Daniel R.
Plate, Lars
Chana-Cuevas, Pedro
Saquel, Cristian
Thielen, Peter
Longo, Kenneth A.
Geddes, Brad J.
Lederkremer, Gerardo Z.
Sharma, Neeraj
Shenkman, Marina
Naphade, Swati
Sardi, S. Pablo
Spichiger, Carlos
Richter, Hans G.
Court, Felipe A.
Tshilenge, Kizito Tshitoko
Ellerby, Lisa M.
Wiseman, R. Luke
Gonzalez-Billault, Christian
Bergink, Steven
Vidal, Rene L.
Hetz, Claudio http://orcid.org/0000-0003-1120-7966
Funding for this research was provided by:
Fondecyt (1180186, 1191003, 3150097, 1150069)
Fondap (15150012)
milenio institute BNI (P09-015-F)
National Institutes of Health (NS092829)
Article History
Received: 5 March 2020
Revised: 6 June 2020
Accepted: 19 June 2020
First Online: 8 July 2020
Compliance with ethical standards
:
: The authors declare no conflict of interest in this study. AAV-IGF2 for gene therapy and its use in misfolded protein diseases as Huntington’s disease (Chile no. 201603282 and PCT. provisional application no. PCT/CL2017/000040).
: MTA may be required for access to AAV-IGF2 and some vectors. All data are available upon request from C.H.